— Cortex Cloud expands the platform with a prevention-first ASPM to automatically stop risks from reaching production — New open AppSec partner ecosystem unifies all data from industry-leading AppSec providers on a single platform for unprecedented cross-vendor visibility Palo Alto Networks® (NASDAQ: PANW), the global cybersecurity leader, today announced Cortex®Cloud™ Application Security Posture Management (ASPM), […]

TheraTears®, a leading brand in dry eye relief under Prestige Consumer Healthcare, is thrilled to announce the launch of its innovative “It's a Science” marketing campaign. This campaign highlights the science-backed formulation of TheraTears® eye drops, emphasizing their unique blend of the five vital electrolytes found in natural tears and the formula's immediate and long-lasting

Annual Contest Celebrates the Creativity and Achievements of Architecture, Design, and Construction Professionals NanaWall, the leader in opening glass wall systems for 40 years, has opened submissions for the NanaAwards2025 Project and Design Competition. Now in its 11th year, the annual contest celebrates the creativity and achievements of architecture and design industry professionals and their

(NASDAQ:CMND),(CNSX:CMND.CN),(CNSX:CMND),(Frankfurt:CWY0.F), IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health

SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) — Otsaw Limited (“OTSAW,” the “Company,” “we,” or “our”), a global developer of autonomous robotics and operations-technology healthcare solutions, today announces that its Autonomous Mobile Service Robots have received Technology Breakthrough Designation under a national group purchasing agreement (“Agreement”) with Premier, Inc., a Delaware corporation (“Premier”). The designation recognizes

(NASDAQ:ZENA),(Boerse Frankfurt – Freiverkehr:49Q),(BMV:ZENA), VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a business technology solution provider specializing in AI-powered drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announced the closing of its seventh Drone as a Service acquisition. Morgan

(NASDAQ:NUWE), MINNEAPOLIS, Aug. 05, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming fluid management, today announced that the first patients have been successfully treated with Aquadex(R) ultrafiltration therapy in a hospital-based outpatient setting. This milestone reflects a major advancement in the company's mission to improve access to fluid

(NYSE MKT:CMT), COLUMBUS, Ohio, Aug. 05, 2025 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today

(CNSX:AIAI),(OTC US:AINMF),(Other OTC:AINMF),(Boerse Frankfurt – Freiverkehr:PF0),(CNSX:AIAI.CN), TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform to analyze results from its

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center GlobeNewswire August 05, 2025 IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind”